LINCOLN, Mass., Jan. 18, 2017 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced that Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath, will present at the next Boston Area Group for Informatics and Modeling (BAGIM) Meeting on Thursday January 19, 2017 at the Broad Institute in Cambridge, MA. Dr. Burke's talk "Quantitative Modeling and Simulation Approaches: Driving Critical Decisions from Research through Clinical Trials" will introduce systems modeling approaches and highlight several case studies which have accelerated the discovery and development of best-in-class therapeutics, and impacted critical decisions, in the continuum from preclinical exploration to clinical research. "I look forward to sharing our experience with modeling and its impact on drug R&D with BAGIM," said Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath. "I'll share some of our examples on how quantitative modeling provides biological understanding, impacts new target proposals, helps with lead generation, streamlines clinical candidate selection, supports IND filings, and helps with clinical trial go/no go decisions."
"BAGIM strives to create a forum for great scientific discussions covering a wide range of topics including data management, visualization, computational chemistry, drug discovery, protein structure, molecular modeling, structure-based drug design, data mining, software tools, and the sharing of goals and experiences," said Michelle Hall, PhD, BAGIM Program chair 2016-2018. "We're excited to have John Burke speak about Applied BioMath's groundbreaking work in quantitative systems pharmacology, a relatively new area of computational modeling, which will bring a new community of modelers to BAGIM."
About Applied BioMath
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, helps biotechnology and pharmaceutical companies answer complex, critical Go/No-go decisions in R&D. Applied BioMath leverages biology, proprietary mathematical modeling and analysis technology, high-performance computing, and decades of industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, and the best path forward. Our involvement shortens project timelines, lowers cost, and increases the likelihood of a best-in-class drug. We provide clarity to complex situations, answer otherwise unanswerable questions, and our approach, when validated in the clinic, is 10x more accurate than traditional methodologies.
Applied BioMath and the Applied BioMath logo are trademarks of Applied BioMath, LLC.
Press contact:
Kristen Zannella
kristen.zannella@appliedbiomath.com
SOURCE Applied BioMath